Ganaton total (itopride / pantoprazole)
/ Abbott
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 12, 2024
Efficacy and safety of pantoprazole and itopride in patients with overlap of gastroesophageal reflux disease and dyspepsia: A prospective, open-label, single-arm pilot study.
(PubMed, JGH Open)
- "The FDC of pantoprazole and itopride showed favorable efficacy and safety in patients with GERD and overlapping dyspepsia refractory to pantoprazole monotherapy. Nevertheless, further studies are warranted."
Journal • Dyspepsia • Gastroenterology • Gastroesophageal Reflux Disease
April 18, 2023
Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India.
(PubMed, Cureus)
- "Results The results show a huge variation (1788.88%) in costs of different brands with the highest being rabeprazole 20 mg and domperidone 10 mg (cost ratio: 18.88, percentage cost variation: 1788.88%) in oral formulation, followed by pantoprazole 40 mg and itopride 150 mg. The minimum cost ratio (1.35) and percentage cost variation (1.35%) is for pantoprazole 40 mg and levosulpiride 75 mg...Conclusion There is a wide variation in the prices of PPIs available in the market, which can inadvertently increase the financial burden of therapy on patients. Physicians need to be made aware of these price differences so that they can choose the best available alternative for patients, which can help in increasing compliance with the prescribed drugs."
HEOR • Journal • Gastroenterology • Gastrointestinal Disorder
April 25, 2022
A PILOT STUDY TO EVALUATE EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION OF PANTOPRAZOLE 40 MG & ITOPRIDE CAPSULES IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE AND OVERLAPPING SYMPTOMS OF DYSPEPSIA.
(DDW 2022)
- "Conclusion Fixed-Dose Combination of Pantoprazole 40 mg and Itopride 150 mg Capsules has excellent efficacy, safety, and tolerability in patients with Gastroesophageal Reflux Disease and Overlapping Symptoms of Dyspepsia who had failed monotherapy with Pantoprazole 40 mg for 8 weeks. Further randomized controlled trials are required to confirm these findings."
Clinical • Dyspepsia • Gastroenterology • Gastroesophageal Reflux Disease • Pain
1 to 3
Of
3
Go to page
1